Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Dell Technologies Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sig who wrote (175279)	1/14/2006 12:21:37 AM
From: stockman_scott	Read Replies (1) \| Respond to of 176387

Zacks Brokerage Buy List: Dell, Eli Lilly, Microsoft Corporation and Wachovia Corporation January 13, 2006 - 6:00 AM EST Today Zacks.com releases the names of four more stocks that are on their coveted Brokerage Buy List portfolio. This portfolio includes just those stocks that currently appear on the core recommended lists of at least three of the top 14 brokerage firms. These stocks are considered the best large-cap stocks to own for the long term according to Wall Street's top players. Since January 2003, this portfolio has generated an annualized double-digit return. Here are four stocks that are currently members of this prestigious list: Dell (Nasdaq:DELL), Eli Lilly (NYSE:LLY), Microsoft Corporation (Nasdaq:MSFT) and Wachovia Corporation (NYSE:WB). View the entire list of stocks on the Brokerage Buy List at at.zacks.com Here are the explanations as to why these stocks are on the Brokerage Buy List: Dell (Nasdaq:DELL) will report its fiscal fourth-quarter numbers in mid-February. Although the company's guidance for the quarter, which was issued in its fiscal third-quarter report from November, disappointed many analysts, Dell nonetheless remains a large-cap stock to own for the long term according to four of the leading brokerages. For the fiscal third quarter, Dell reported non-GAAP earnings per share of 39 cents, which was up 18% year-over-year, while company revenues advanced 11% to $13.9 billion. Eli Lilly (NYSE:LLY) recently signed an agreement with Alkermes, Inc. to develop and commercialize inhaled formulations of parathyroid hormone for the treatment of osteoporosis. Eli Lilly will have exclusive worldwide rights to products resulting from the collaboration and will pay Alkermes royalties based on products sales. According to three of the top brokerages, Eli Lilly remains a large-cap stock to own for the long term. The company will report its fourth-quarter numbers later this month. In December, the company said it is uniquely positioned to deliver sustained earnings growth, due to its products, pipeline and the fact that the firm expects no major patent expirations for the rest of the decade. Microsoft Corporation (Nasdaq:MSFT) announced in mid-December that its Board of Directors increased its quarterly dividend by 12.5% to 9 cents per share from the previous quarter's dividend. The company said it remains confident in its growth prospects and has an exciting product line-up. Microsoft will report its fiscal second- quarter numbers later this month. For its fiscal first quarter, Microsoft posted earnings per share of 31 cents, excluding items, which exceeded the consensus by about 3%. Revenue reached $9.74 billion, or 6% ahead of $9.19 billion a year earlier. The company is considered one of the best large-cap stocks to own for the long-term, according to six of the leading brokerages. Wachovia Corporation (NYSE:WB) will announce its fourth-quarter numbers next week. For its third quarter, earnings per share, excluding items, reached $1.09, compared to $1.00 in the year-ago quarter. The result also topped the consensus by almost 1%. Revenue increased 19%. Wachovia stated that its record results reflect solid execution on its revenue strategies and merger integration savings, along with improving efficiency. Wachovia remains a favorite with three of the leading brokerage firms. To discover all the other profitable stock portfolios at Zacks.com, use this link: at.zacks.com About Zacks Brokerage Buy List Zacks has developed many successful ways for individual investors to profit from the stock picking prowess of Wall Street professionals. The Brokerage Buy List is yet another powerful tool that investors can wield in order to improve their investment results. This portfolio is comprised of the core stocks recommended by at least three of the Top 14 brokerage firms. These are the kind of large-cap stocks that are best for long- term investors. Since January 2003, this portfolio has generated an annualized double-digit return. To learn more about the Brokerage Buy List, go to at.zacks.com About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind Zacks work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. The goal is to unlock these pros' profitable insights for individual investors hard-pressed to find this valuable information in one source. A free subscription to "Profit from the Pros" weekly e-mail newsletter provides the best way to use these experts' insights for more profitable investing. Register for a free subscription to the Profit from the Pros newsletter at at.zacks.com Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. (a) The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard and Poor's. The S&P 500 includes the reinvestment of all dividends, no transaction costs, and represents the gross returns before management fees. Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security. Zacks.com Jim Giaquinto, 312-630-9880 x 268 pr@zacks.com www.Zacks.com Source: Business Wire (January 13, 2006 - 6:00 AM EST)